FGFR2 and neoplasm: The antitumor activity of CPL304110 was investigated in the following four subcutaneous xenograft tumor models with confirmed genetic alterations in FGFR genes: FGFR1-overexpressing lung xenografts (H1581), FGFR2-amplified gastric xenograft (SNU16), and two FGFR3-dependent bladder xenografts models (RT-112 and UM-UC-14) (Figure 8).